Lithium levels in human and mouse brains influence Alzheimer’s disease effects, but targeted replacement therapy may hold the ...

A cerebrospinal fluid (CSF) biomarker test detected tau protein in Alzheimer's disease years before it formed into pathologic fibrillary tangles. In neuropathological assessments, antibodies ...

Tyrosine 29 tau phosphorylation appears to increase the stability of tau and prevents its clearance via autophagy, a cellular maintenance process in which cytoplasmic contents are digested and their ...

Specific pathways of Alzheimer's disease and FTLD-non-tau (FTLD-TDP linked to PGRN mutations) merge at tau phosphorylation. The mislocalization of phosphorylated tau to dendritic spines ...

This promotes Tau phosphorylation and aggregation, which can lead to exacerbated Aβ toxicity, causing a detrimental cycle that accelerates AD progression. Figure 3.

But Alzheimer’s disease is complex, and abnormal tau isn’t the only observable brain change. Deposits of beta-amyloid protein, known as plaques, are another hallmark.

While much research related to Alzheimer’s disease has concentrated on identifying ways to reduce the buildup of amyloid plaques — which form when sticky protein fragments known as amyloid beta ...

Likewise, in a subgroup of 147 participants who had a tau PET scan with the MK6240 tracer, tangle load in the earliest Braak regions correlated with amyloid load only in the Ast+ group, again ...

Researchers have used an experimental drug to slow the phosphorylation of tau, which causes it to aggregate into neuron-damaging tangles in Alzheimer's disease Depositphotos View 1 Images ...

A blood biomarker that measures astrocyte reactivity may help determine who, among cognitively unimpaired older adults with amyloid-beta, will go on to develop Alzheimer's disease (AD), new ...